INTU stock decline and buying opportunity

PARAGRAPH 1 --- What happened: Intuitive Surgical (ISRG) stock has declined 31% YTD, driven by a slower procedure growth guide and concerns about Obamacare changes hurting demand. Despite this, ISRG has beaten EPS estimates for five consecutive quarters, with Q2 EPS at $2.80 vs. $2.50 consensus. ISRG's razor-and-razorblade model now delivers 85% recurring revenue across 11,710 da Vinci systems, while competitors like Medtronic (MDT) and Johnson & Johnson (JNJ) remain early or pre-commercial in robotic surgery.

PARAGRAPH 2 --- Market impact: The significant decline in ISRG stock, compared to peers MDT and Stryker (SYK) which fell less than 10% YTD, suggests the market has overcorrected. This has created a buying opportunity for long-term investors, as indicated by bullish sentiment from analysts like Citi. However, concerns about AI disruption and earnings growth have led Jensen Investment Management to reduce their position in Intuit (INTU), another tech stock, highlighting broader investor caution.

PARAGRAPH 3 --- What to watch next: Investors should closely monitor ISRG's earnings on July 16, where guidance for procedure growth will be crucial. Additionally, regulatory decisions regarding Obamacare and any updates on competitors' robotic surgery offerings will shape the narrative. Lastly, technical levels around ISRG's 28% discount to Wall Street consensus will provide insight into potential support or resistance points.